These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. Snyder RW; Lambrou FH; Williams GA Arch Ophthalmol; 1987 Sep; 105(9):1277-80. PubMed ID: 3115240 [TBL] [Abstract][Full Text] [Related]
84. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model. Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982 [TBL] [Abstract][Full Text] [Related]
85. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator. Wootton DM; Popel AS; Alevriadou BR Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013 [TBL] [Abstract][Full Text] [Related]
86. Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2005 Mar; 16(2):125-33. PubMed ID: 15741800 [TBL] [Abstract][Full Text] [Related]
88. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Konieczynska M; Fil K; Bazanek M; Undas A Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139 [TBL] [Abstract][Full Text] [Related]
89. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro. Lourenço DM; Dosne AM; Kher A; Samama M Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812 [TBL] [Abstract][Full Text] [Related]
90. The effect of anticoagulation with subcutaneously delivered polyethylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model. Alexander B; Burnand KG; Lattimer CL; Humphries J; Gaffney PJ; Eastham D; Smith A Thromb Res; 2004; 113(2):155-61. PubMed ID: 15115671 [TBL] [Abstract][Full Text] [Related]
91. A fusion protein with improved thrombolytic effect and low bleeding risk. Wang X; Zhang G; Wang L; Zhang Q; Qin Y; Wu C; Yu A Thromb Haemost; 2009 Dec; 102(6):1194-203. PubMed ID: 19967151 [TBL] [Abstract][Full Text] [Related]
92. Biochemical and biophysical conditions for blood clot lysis. Sabovic M; Blinc A Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642 [TBL] [Abstract][Full Text] [Related]
93. Enhanced clot lysis by a single point mutation in a reteplase variant. Chen S; Chen D; Liu Y; Xu Y; Lin H; Cheng Y; Li J; Meng C; Liang M; Yuan C; Huang M Br J Haematol; 2022 Feb; 196(4):1076-1085. PubMed ID: 34783361 [TBL] [Abstract][Full Text] [Related]
94. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Weitz JI; Leslie B; Hudoba M Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024 [TBL] [Abstract][Full Text] [Related]
95. Enhancement of fibrinolysis in vitro by ultrasound. Francis CW; Onundarson PT; Carstensen EL; Blinc A; Meltzer RS; Schwarz K; Marder VJ J Clin Invest; 1992 Nov; 90(5):2063-8. PubMed ID: 1430229 [TBL] [Abstract][Full Text] [Related]
96. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925 [TBL] [Abstract][Full Text] [Related]
98. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. Pannell R; Li S; Gurewich V PLoS One; 2015; 10(3):e0122018. PubMed ID: 25811605 [TBL] [Abstract][Full Text] [Related]
99. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Hantgan RR; Jerome WG; Hursting MJ Blood; 1998 Sep; 92(6):2064-74. PubMed ID: 9731064 [TBL] [Abstract][Full Text] [Related]
100. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. Carr ME; Dent RM; Carr SL J Lab Clin Med; 1996 Jul; 128(1):83-8. PubMed ID: 8759939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]